ARTHUR J GALLAGHER & CO.
Risk management and benefits solutions should be about more than just placing coverage or selecting a plan. It’s about growing your business and protecting your dreams. It’s about ensuring your employees are properly engaged. Everyday our clients face massive challenges across a range of issues. Gallagher’s advisors understand your business and how hard you work to deliver on your promises. We’re your global partner in achieving your goals. And that only begins to describe the shared values, corporate culture and passion for excellence that define The Gallagher Way of doing business. Arthur J. Gallagher & Co. - the only insurance broker on the Ethisphere Institute’s list of the World’s Most Ethical Companies.
BioHub is situated on Birmingham Research Park, a long-standing and successful joint venture between the University of Birmingham and Birmingham City Council. Birmingham Research Park is at the heart of the Edgbaston Medical Quarter, a vibrant and collaborative health science community. This cluster is home to 64% of the City’s healthcare economy including 180 medical organisations, 44 GP clinics and routine care facilities and 80 hospitals and specialist care centres. The BioHub is a brand new, fully serviced biomedical laboratory specifically designed to provide entrepreneurs and innovative start-ups with access to affordable laboratory facilities and equipment.
CANCER RESEARCH TECHNOLOGY
Cancer Research Technology (CRT) is a specialist commercialisation and development company, which aims to develop new discoveries in cancer research for the benefit of cancer patients. CRT works closely with leading international cancer scientists and their institutes to protect intellectual property arising from their research and to establish links with commercial partners. CRT facilitates the discovery, development and marketing of new cancer therapeutics, vaccines, diagnostics and enabling technologies. CRT is a wholly owned subsidiary of Cancer Research UK, the world’s leading cancer charity dedicated to saving lives through research.
Coulter Partners is a retained executive search consultancy exclusively focussed on Life Sciences. Founded by Bianca Coulter in 2003, we combine access to our global network of talent with meticulous contextual research to locate and deliver the best candidates available for assignments in every functional area of the Life Science sector. Our diverse, multi lingual team of consultants combines PhD level scientific understanding with deep sector experience. Our clients range from early stage, venture backed businesses to Global Pharmaceutical companies.
We serve our clients globally from our locations in London (UK), Cambridge (Massachusetts), Princeton (New Jersey) and Nyon (Switzerland).
Edinburgh BioQuarter is an academic medical centre with a focus on interdisciplinary research and translational medicine, with particular strengths in regenerative medicine and connected health. The campus brings together clinicians, industrialists, patients, scientists, state-of-the-art pre-clinical and clinical research facilities, and an academic teaching hospital on one campus. The BioQuarter links a broad range of leading companies and research institutions, providing world class facilities with one-stop access to a combination of pre-clinical and clinical excellence.
GILL JENNINGS & EVERY
As a leading European patent and trade mark attorney firm, Gill Jennings & Every LLP can help you turn your innovations, brands and designs into commercial success. We understand the importance of intellectual property to your business and by providing clear, creative and expert advice we can assist you in protecting, exploiting and managing your IP assets to maximise their value. We are consistently recognised by the leading UK legal directories, Chambers, Legal 500 and Managing Intellectual Property, a testament to the quality of our advice and the valued role we play in supporting our clients
Horizon is the leading life science company supplying research tools to organisations engaged in genomics research and the development of personalised medicines. The Company is a trusted supplier of genetically-defined cell lines, reporter gene assay kits, genomic reference standards and contract research services to organizations engaged in bio-pharmaceutical process optimization, drug discovery & development, and clinical diagnostic development. Horizon aspires to provide science-driven research solutions that lead to the advancement in the understanding of the genetic basis of disease and the delivery of better healthcare outcomes for patients.
Imperial Innovations is focused on commercialising leading UK academic research sourced from the ‘golden triangle’ formed between Cambridge, Oxford and London. Imperial Innovations is a technology commercialisation company that combines the activities of technology transfer, intellectual property protection and licensing, company incubation, and investment. Innovations is focused on commercialising the most promising UK academic research across a broad range of technology sectors, and has developed particular expertise in: therapeutics, medtech, engineering and materials and information communication technology.
Biotech companies face a unique set of challenges. In IP development stages, Biotechs consume vast amounts of capital, so early investor trust is crucial. As the IP moves to reality and approaches the market, IPO and finally M&A activities become the focus; here again, trust is the key to success – in security of the IP, the value of the offering, and the solidity of the company. Intralinks has built a reputation of trust in the Biotech community with a history of providing secure spaces and transactional tools for raising start-up capital; for keeping assets valuable and investor-ready; for taking companies public; and for exchanging critical, sensitive M&A information. Intralinks helps build Biotechs by protecting their most valuable assets along every step of the journey. We stand behind Biotechs, so their ideas can move forward.
JAMES COWPER KRESTON
With strategically placed offices in the South of England, membership of Kreston International and a global network of independent accountants and business advisers, James Cowper Kreston is ideally placed to provide informed local, national and international advice. An integrated approach lies at the very heart of our business ethos. We consider all the angles when it comes to providing the widest levels of help, service and support for our clients, and apply the same approach to our people. We believe that a constructive work environment ultimately benefits everyone involved, including you. Whatever your accounting or business advisory needs, our specialist teams work together on your behalf, placing a high value on sound communication. We understand the factors helping and hindering your immediate and long-term aspirations, and our shared vision is to help you succeed.
NetScientific’s mission is to build a transatlantic biomedical and healthcare group funding and developing technologies that offer transformative benefits to people’s lives and society.
NetScientific funds, develops and manages early/mid-stage healthcare technology companies sourced from strategic partnerships and relationships in USA and Europe with a primary focus on Digital health, Diagnostics and Therapeutics. These represent highly attractive growth markets where breakthrough technology solutions are in high demand.
NetScientific is an active investor providing extensive management support. This can involve the senior management team initially taking leadership roles in companies and building dedicated management teams as the companies develop and grow.
Evgen is a clinical stage drug development company focused on the treatment of cancer and neurological conditions. Evgen’s pipeline is based on our proprietary Sulforadex® technology, and includes a number of synthetic, stabilised analogues of the naturally occurring compound sulforaphane. Many peer-reviewed scientific papers have identified the medical potential of sulforaphane in multiple indications. Our objective is to use our Sulforadex® technology to turn this scientific promise into commercially successful products, addressing important clinical needs.